EP2830620A4 - 4-aminopyridine à titre d'agent thérapeutique pour l'amyotrophie spinale (sma) - Google Patents

4-aminopyridine à titre d'agent thérapeutique pour l'amyotrophie spinale (sma)

Info

Publication number
EP2830620A4
EP2830620A4 EP13769101.0A EP13769101A EP2830620A4 EP 2830620 A4 EP2830620 A4 EP 2830620A4 EP 13769101 A EP13769101 A EP 13769101A EP 2830620 A4 EP2830620 A4 EP 2830620A4
Authority
EP
European Patent Office
Prior art keywords
aminopyridine
therapeutic agent
muscular atrophy
spinal muscular
spinal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP13769101.0A
Other languages
German (de)
English (en)
Other versions
EP2830620A1 (fr
Inventor
Brian Mccabe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Columbia University in the City of New York
Original Assignee
Columbia University in the City of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Columbia University in the City of New York filed Critical Columbia University in the City of New York
Publication of EP2830620A1 publication Critical patent/EP2830620A1/fr
Publication of EP2830620A4 publication Critical patent/EP2830620A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
EP13769101.0A 2012-03-26 2013-03-26 4-aminopyridine à titre d'agent thérapeutique pour l'amyotrophie spinale (sma) Withdrawn EP2830620A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261615466P 2012-03-26 2012-03-26
PCT/US2013/033952 WO2013148740A1 (fr) 2012-03-26 2013-03-26 4-aminopyridine à titre d'agent thérapeutique pour l'amyotrophie spinale (sma)

Publications (2)

Publication Number Publication Date
EP2830620A1 EP2830620A1 (fr) 2015-02-04
EP2830620A4 true EP2830620A4 (fr) 2015-12-09

Family

ID=49261189

Family Applications (1)

Application Number Title Priority Date Filing Date
EP13769101.0A Withdrawn EP2830620A4 (fr) 2012-03-26 2013-03-26 4-aminopyridine à titre d'agent thérapeutique pour l'amyotrophie spinale (sma)

Country Status (4)

Country Link
EP (1) EP2830620A4 (fr)
JP (1) JP2015512409A (fr)
CN (1) CN104334174A (fr)
WO (1) WO2013148740A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3029113A1 (fr) * 2014-12-02 2016-06-03 Univ Paris-Sud Composes pour le traitement des maladies mitochondriales
CN106511293B (zh) * 2015-09-11 2020-08-04 法德生技药品股份有限公司 含有达方吡啶的缓释口服制剂及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010048273A2 (fr) * 2008-10-21 2010-04-29 President And Fellows Of Harvard College Procédés et composés pour le traitement de troubles neurodégénératifs
WO2012050884A2 (fr) * 2010-09-28 2012-04-19 President And Fellows Of Harvard College Glycosides cardiaques qui sont de puissants inhibiteurs de l'expression du gène de l'interféron bêta

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5952357A (en) * 1993-12-23 1999-09-14 Cornell Research Foundation, Inc. Treating diseases of the anterior horn cells
JP2003530432A (ja) * 2000-04-12 2003-10-14 ミナーヴァ・バイオテクノロジーズ・コーポレーション 神経変性疾患の治療
US8445503B2 (en) * 2009-12-23 2013-05-21 Elan Pharmaceuticals, Inc. Inhibitors of polo-like kinase
WO2011098449A1 (fr) * 2010-02-10 2011-08-18 Novartis Ag Procédés et composés pour la croissance de muscle
JP5549260B2 (ja) * 2010-02-16 2014-07-16 富士通株式会社 ストレージシステムおよびデータ書込み方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010048273A2 (fr) * 2008-10-21 2010-04-29 President And Fellows Of Harvard College Procédés et composés pour le traitement de troubles neurodégénératifs
WO2012050884A2 (fr) * 2010-09-28 2012-04-19 President And Fellows Of Harvard College Glycosides cardiaques qui sont de puissants inhibiteurs de l'expression du gène de l'interféron bêta

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2013148740A1 *

Also Published As

Publication number Publication date
CN104334174A (zh) 2015-02-04
EP2830620A1 (fr) 2015-02-04
WO2013148740A1 (fr) 2013-10-03
JP2015512409A (ja) 2015-04-27

Similar Documents

Publication Publication Date Title
IL254045B (en) Compounds for the treatment of spinal muscular atrophy
HK1202069A1 (en) Compounds for treating spinal muscular atrophy
HK1200056A1 (en) Compounds for treating spinal muscular atrophy
HK1202527A1 (en) Compounds for treating spinal muscular atrophy
HK1202059A1 (en) Compounds for treating spinal muscular atrophy
HK1206297A1 (en) Pharmaceutical compositions for combination therapy
GB201106527D0 (en) Therapeutic apparatus
EP2739232A4 (fr) Équipement médical
EP2523660A4 (fr) Formulations pour anesthésie locale se solidifiant pour la gestion de la douleur
EP2799083A4 (fr) Agent de prévention de l'atrophie musculaire
HRP20190050T1 (hr) Farmaceutski pripravci za kombinacijsku terapiju
HK1219224A1 (zh) 角結膜病症的治療劑
ZA201301458B (en) Therapeutic agent for pain
EP2830620A4 (fr) 4-aminopyridine à titre d'agent thérapeutique pour l'amyotrophie spinale (sma)
HK1182712A1 (en) Therapeutic agents 976 976
SG11201402226PA (en) Therapeutic agent for arthrosis
EP2548580A4 (fr) Produit pharmaceutique pour la thérapie de pseudo-exercice
EP2641609A4 (fr) Agent thérapeutique pour une dystrophie musculaire
GB201221053D0 (en) Patient movement monitor
EP2627655A4 (fr) Analogues 5,6,5-tricycliques thérapeutiques
AU2012902957A0 (en) Bed Patient Monitor
GB201201475D0 (en) Patient mobility aid
HUE043019T2 (hu) Gyógyszerészeti készítmények kombinációs terápia céljára
GB201101807D0 (en) Modified medical tool

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20141027

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 21/00 20060101ALI20150714BHEP

Ipc: A61K 31/4409 20060101AFI20150714BHEP

RA4 Supplementary search report drawn up and despatched (corrected)

Effective date: 20151110

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/4409 20060101AFI20151104BHEP

Ipc: A61P 21/00 20060101ALI20151104BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20160608